Antisense Therapeutics Limited News - ANP

Long COVID-19 study identifies novel blood markers as potential diagnostic and therapeutic targets

Long COVID-19 study identifies novel blood markers as potential diagnostic and therapeutic targets World first study utilizing Somalogic...

Antisense Therapeutics Announces a Poster Presentation on the Muscular Dystrophy Association Virtual Conference 2020 website

Antisense Therapeutics (ASX:ANP | US OTC:ATHJY), an Australian biopharmaceutical company developing and commercializing antisense pharmaceuticals...

Antisense ATL1102 Final Phase II DMD Results Meet Primary Endpoint and Exceed Expectations on Secondary Endpoints

Primary endpoint met with confirmation of drug’s safety and tolerability Strong effects on secondary endpoints on activity markers and disease...

Antisense Therapeutics Announces Appointment of US-based Consultant Medical Director

Clinician with deep experience in DMD drug development (ex-Sarepta Therapeutics Director) On the ground presence in the US to accelerate...

ATL1102 for MS - Phase II trial results published in the leading Medical Journal Neurology

ATL1102 for MS - Phase II trial results published in the leading Medical Journal Neurology PR Newswire TOORAK, Australia, Sept. 22, 2014 TOORAK...

ATL1103 Phase II Trial - Successful Efficacy Results

ATL1103 Phase II Trial - Successful Efficacy Results - Primary efficacy endpoint met with a statistically significant reduction of sIGF-I levels...

ATL1103 Acromegaly Phase II Trial Dosing Completed

ATL1103 Acromegaly Phase II Trial Dosing Completed -Primary efficacy results on track to be received by end of August 2014 PR Newswire TOORAK...

ATL1102 for MS - Toxicology Study Main Findings

ATL1102 for MS - Toxicology Study Main Findings PR Newswire TOORAK, Australia, April 1, 2014 TOORAK, Australia, April 1, 2014 /PRNewswire/...

ATL1103 Acromegaly Phase II Trial Recruitment Completed

ATL1103 Acromegaly Phase II Trial Recruitment Completed - 24 patients now recruited into the trial - 16 patients have completed dosing - No...

ATL1102 for Stem Cell Mobilisation Trial Commencement

ATL1102 for Stem Cell Mobilisation Trial Commencement PR Newswire TOORAK, Australia, March 17, 2014 TOORAK, Australia, March 17, 2014...

Antisense Therapeutics Selected to Present at Biotech Showcase™ 2014

Antisense Therapeutics Selected to Present at Biotech Showcase™ 2014 PR Newswire SAN FRANCISCO, Jan. 7, 2014 SAN FRANCISCO, Jan. 7, 2014...

Positive Results Achieved from Interim Analysis of ATL1103 Phase II Trial

Positive Results Achieved from Interim Analysis of ATL1103 Phase II Trial PR Newswire TOORAK, Australia, Dec. 23, 2013 TOORAK, Australia, Dec...

ANP to present at and attend major US investment, partnering and industry conferences

ANP to present at and attend major US investment, partnering and industry conferences PR Newswire TOORAK, Australia, Aug. 28, 2013 TOORAK...

Teva & ANP Announce That ATL/TV1102, a Novel Drug for the Treatment of Relapsing Remitting Multiple Sclerosis (RRMS), Demonstrat

Teva Pharmaceutical Industries Ltd. (NASDAQ: Teva) and Antisense Therapeutics Ltd. (ASX: ANP) announced today that ATL/TV1102, a...

Directorate Change

RNS Number:5859U Anglo American Platinum Corp Ld 23 January 2004 Issuer Long Name : Anglo American Platinum Corporation Limited...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Antisense Therapeutics Limited (ANP)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

ANP News

Long COVID-19 study identifies novel blood markers as potential diagnostic and therapeutic targets

Antisense Therapeutics Announces a Poster Presentation on the Muscular Dystrophy Association Virtual Conference 2020 website

Antisense ATL1102 Final Phase II DMD Results Meet Primary Endpoint and Exceed Expectations on Secondary Endpoints

Antisense Therapeutics Announces Appointment of US-based Consultant Medical Director

ATL1102 for MS - Phase II trial results published in the leading Medical Journal Neurology

ATL1103 Phase II Trial - Successful Efficacy Results

ATL1103 Acromegaly Phase II Trial Dosing Completed

ATL1102 for MS - Toxicology Study Main Findings

ATL1103 Acromegaly Phase II Trial Recruitment Completed

ATL1102 for Stem Cell Mobilisation Trial Commencement

Antisense Therapeutics Selected to Present at Biotech Showcase™ 2014

Positive Results Achieved from Interim Analysis of ATL1103 Phase II Trial

ANP to present at and attend major US investment, partnering and industry conferences

Teva & ANP Announce That ATL/TV1102, a Novel Drug for the Treatment of Relapsing Remitting Multiple Sclerosis (RRMS), Demonstrat

Directorate Change

ANP Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Antisense Therapeutics Limited (ANP) News

Antisense Therapeutics Limited (ANP)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

ANP News

Long COVID-19 study identifies novel blood markers as potential diagnostic and therapeutic targets

Antisense Therapeutics Announces a Poster Presentation on the Muscular Dystrophy Association Virtual Conference 2020 website

Antisense ATL1102 Final Phase II DMD Results Meet Primary Endpoint and Exceed Expectations on Secondary Endpoints

Antisense Therapeutics Announces Appointment of US-based Consultant Medical Director

ATL1102 for MS - Phase II trial results published in the leading Medical Journal Neurology

ATL1103 Phase II Trial - Successful Efficacy Results

ATL1103 Acromegaly Phase II Trial Dosing Completed

ATL1102 for MS - Toxicology Study Main Findings

ATL1103 Acromegaly Phase II Trial Recruitment Completed

ATL1102 for Stem Cell Mobilisation Trial Commencement

Antisense Therapeutics Selected to Present at Biotech Showcase™ 2014

Positive Results Achieved from Interim Analysis of ATL1103 Phase II Trial

ANP to present at and attend major US investment, partnering and industry conferences

Teva & ANP Announce That ATL/TV1102, a Novel Drug for the Treatment of Relapsing Remitting Multiple Sclerosis (RRMS), Demonstrat

Directorate Change

ANP Discussion

Your Recent History